ABSTRACT
Background Hospital-based biobanks have become an increasingly prominent resource for evaluating the clinical impact of disease-related polygenic risk scores (PRS). However, biobank cohorts typically rely on selection of volunteers who may differ systematically from non-participants.
Methods PRS weights for schizophrenia, bipolar disorder, and depression were derived using summary statistics from the largest available genomic studies. These PRS were then calculated in a sample of 24,153 European ancestry participants in the Mass General Brigham (MGB) Biobank. To correct for selection bias, we fitted a model with inverse probability (IP) weights estimated using 1,839 sociodemographic and clinical features extracted from electronic health records (EHRs) of eligible MGB patients. Finally, we tested the utility of a modular specification of the IP weight model for selection.
Results Case prevalence of bipolar disorder among participants in the top decile of bipolar disorder PRS was 10.0% (95% CI: 8.8%-11.2%) in the unweighted analysis but only 6.2% (5.0%-7.5%) when selection bias was accounted for using IP weights. Similarly, case prevalence of depression among those in the top decile of depression PRS was reduced from 33.5% (31.7%-35.4%) in the unweighted analysis to 28.9% (25.8%-31.9%) after IP weighting. Modular correction for selection bias in intermediate selection steps did not substantially impact PRS effect estimates.
Conclusions Non-random selection of participants into volunteer biobanks may induce clinically relevant selection bias that could impact implementation of PRS and risk communication in clinical practice. As efforts to integrate PRS in medical practice expand, recognition and mitigation of these biases should be considered.
Competing Interest Statement
Dr. Smoller is a member of the Leon Levy Foundation Neuroscience Advisory Board, the Scientific Advisory Board of Sensorium Therapeutics, and has received honoraria for internal seminars at Biogen, Inc and Tempus Labs. He is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments.
Funding Statement
This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR002541) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health. YAF is supported by the National Taiwan University Higher Education Sprout Project (NTU-110L8810) within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. EWK was supported by 5U01HG008685. TG was supported in part by NIA R00AG054573, NHGRI U01HG008685 and NHGRI U01HG011723. JWS was supported in part by NIMH R01MH118233, NHGRI U01HG008685, and a gift from the Demarest Lloyd, Jr. Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted as part of the PsycheMERGE Consortium, under approval from the Mass General Brigham Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
